Portal de Periódicos da CAPES

Open peer commentary on “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions”

2023; Elsevier BV; Volume: 9; Issue: 4 Linguagem: Inglês

10.1002/trc2.12437

2352-8737

Sam Gandy,

Multiple Sclerosis Research Studies

To the Editor, The editorial by Greenberg et al.1 eloquently details some well-known but rarely discussed major limitations in the diversity of patient populations enrolled in recent clinical trials with anti-amyloid antibodies (AAAs). I regret to say that I have written about these drugs in several venues2-6 but failed to mention these limitations. I endorse these sentiments completely and unconditionally, and I intend to cite these limitations as I counsel patients for whom AAAs are under consideration. The failures in this area are especially painful when one realizes that the potentially modifiable dementia risk factors of hypertension, diabetes, obesity, low high-density lipoproteins, and poor sleep hygiene are more prevalent in Black and South Asian populations.7 In failing to include these groups, we risk overlooking the patients that may be most likely to benefit. In recognition of Black patients’ past exploitation by the medical and scientific community, the DHGI will consult with local Black communities on research directions. The institute will also rely on an ethics advisory committee that includes local Black community leaders, an ethicist from Africa, a faith leader, and other experts to ensure all research activities are ethical and culturally appropriate. What's driving the new project … is Black communities and researchers having a “seat at the table.” We welcome this opportunity to start righting centuries of wrongs. The author was supported as follows: NIH grants U01AG046170, RF1AG058469, RF1AG059319, R01AG061894, P30 AG066514 to Mary Sano, and Cure Alzheimer's Fund. Dr. Gandy is a co-founder of Recuerdo Pharmaceuticals. He has served as a consultant in the past for J&J, Diagenic, and Pfizer, and he currently consults for Cognito Therapeutics, GLG Group, SVB Securities, Guidepoint, Third Bridge, MEDACORP, Altpep, Vigil Neurosciences, and Eisai. He has received research support in the past from Warner-Lambert, Pfizer, Baxter, and Avid. He currently receives research support from the NIH and the Cure Alzheimer's Fund. Author disclosures are available in the supporting information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.